Earnings summaries and quarterly performance for ADIAL PHARMACEUTICALS.
Executive leadership at ADIAL PHARMACEUTICALS.
Board of directors at ADIAL PHARMACEUTICALS.
Research analysts covering ADIAL PHARMACEUTICALS.
Recent press releases and 8-K filings for ADIL.
Adial Pharmaceuticals Announces 1-for-25 Reverse Stock Split
ADIL
Delisting/Listing Issues
Proxy Vote Outcomes
- Adial Pharmaceuticals, Inc. will effect a 1-for-25 reverse stock split.
- The split becomes effective on February 5, 2026, at 11:59 p.m. Eastern Time, with trading on a split-adjusted basis beginning February 6, 2026.
- The primary purpose of the reverse stock split is to regain compliance with Nasdaq's minimum bid price requirement of at least $1.00 per share.
- This action will reduce the number of outstanding shares from approximately 27.8 million to approximately 1.1 million.
- Stockholders will receive a cash payment in lieu of fractional shares.
2 days ago
Adial Pharmaceuticals Applauds Congressional Directive on Clinical Trial Endpoints
ADIL
New Projects/Investments
- Adial Pharmaceuticals (ADIL) announced that a new congressional directive, signed into law on February 4, 2026, mandates the U.S. Food and Drug Administration (FDA) and the National Institute on Drug Abuse (NIDA) to collaborate on establishing alternative clinical trial endpoints for substance use disorders, including Alcohol Use Disorder (AUD).
- These new endpoints will consider measures beyond abstinence, such as reduced cravings or reduced disorder severity, which Adial believes will modernize regulatory expectations and support innovation.
- Adial's lead investigational therapy, AD04, designed to address AUD using a precision medicine approach, is aligned with these non-abstinence recovery outcomes, and the company believes this action enhances its regulatory path.
3 days ago
Adial Pharmaceuticals Announces 1-for-25 Reverse Stock Split
ADIL
Delisting/Listing Issues
- Adial Pharmaceuticals, Inc. (ADIL) will effect a 1-for-25 reverse stock split becoming effective on February 5, 2026, at 11:59 p.m. Eastern Time, with split-adjusted trading commencing on February 6, 2026.
- The primary purpose of the reverse split is to regain compliance with Nasdaq's minimum bid price requirement and to make the bid price more appealing to a broader range of investors.
- This action will proportionally reduce the number of outstanding shares from approximately 27.8 million to about 1.1 million.
3 days ago
Adial Pharmaceuticals Announces Patent Application for AD04 to Extend IP Exclusivity
ADIL
New Projects/Investments
- Adial Pharmaceuticals announced the publication of the international patent application for AD04, which was filed in July 2024.
- This patent, once granted, is anticipated to protect Adial's core assets until at least 2045.
- AD04 is the company's lead investigational therapeutic agent for treating Alcohol Use Disorder (AUD) in heavy drinking patients.
- Adial is currently planning a new Phase 3 clinical trial program for AD04 for AUD.
Jan 14, 2026, 2:00 PM
Adial Pharmaceuticals Announces Warrant Inducement Transaction
ADIL
- Adial Pharmaceuticals, Inc. announced a warrant inducement agreement with an existing institutional investor, generating approximately $2.86 million in gross proceeds.
- The transaction involved the immediate exercise of existing Series C-1 and Series E Warrants to purchase an aggregate of 9,215,675 shares of common stock at a reduced exercise price of $0.31 per share.
- In consideration for the immediate exercise, the investor received new unregistered Series F Warrants to purchase up to 13,823,512 shares of common stock, with an exercise price of $0.31.
- The new Series F Warrants will be exercisable upon shareholder approval and will expire 24 months following the approval date.
- The company intends to use the net proceeds from this transaction for working capital and other general corporate purposes.
Dec 1, 2025, 9:05 PM
Adial Pharmaceuticals Reports Q3 2025 Financial Results and Provides Business Update
ADIL
Earnings
New Projects/Investments
Guidance Update
- Adial Pharmaceuticals reported cash and cash equivalents of $4.6 million as of September 30, 2025, compared to $5.9 million as of June 30, 2025. The company anticipates these funds will cover operating expenses into the second quarter of 2026.
- The Net Loss for the three months ended September 30, 2025, was $1.8 million, a decrease from a $2.2 million net loss in the prior year's comparable period, primarily due to reduced research and development spending.
- The company received valuable guidance from the FDA during an End of Phase 2 (EOP2) meeting regarding the planned adaptive Phase 3 study design for AD04, its lead investigational drug for Alcohol Use Disorder (AUD).
- Adial partnered with Genomind to validate a cheek swab collection method for identifying eligible AD04 patients, a critical step for clinical trials and future commercial use, which the FDA confirmed as a Non-Significant Risk for the Phase 3 study.
Nov 14, 2025, 1:35 PM
Adial Pharmaceuticals Reports Q3 2025 Financial Results and Provides AD04 Development Update
ADIL
Earnings
Guidance Update
New Projects/Investments
- Adial Pharmaceuticals reported a net loss of $1.8 million for the third quarter of 2025, an improvement from $2.2 million in the same period of 2024, primarily due to lower R&D spending.
- The company's cash and cash equivalents stood at $4.6 million as of September 30, 2025, and are expected to fund operating expenses into the second quarter of 2026.
- Adial successfully completed an End of Phase 2 (EOP2) meeting with the FDA for its lead investigational drug, AD04, receiving guidance on critical elements of its planned adaptive Phase 3 study design for Alcohol Use Disorder (AUD).
- The company updated its provisional patent application for AD04 in July 2025, which, once granted, is expected to protect Adial's core assets until at least 2045.
Nov 14, 2025, 1:30 PM
Adial Pharmaceuticals Completes Validation of AD04 Genetic Test with Genomind
ADIL
Product Launch
New Projects/Investments
- Adial Pharmaceuticals announced the successful analytical validation of a cheek swab collection method for its AD04 therapy, developed in partnership with Genomind, to identify patients for the upcoming Phase 3 program and future commercial use.
- The FDA confirmed that the use of this genetic test in the Phase 3 study is a Non-Significant Risk (NSR), meaning an Investigational Device Exemption (IDE) application is not required.
- This milestone advances AD04 towards FDA registration and supports future commercial activities, with a new patent filing expected to extend market exclusivity to 2045.
Oct 9, 2025, 12:30 PM
Adial Pharmaceuticals receives favorable FDA feedback for AD04 Phase 3 trial design
ADIL
New Projects/Investments
Product Launch
- Adial Pharmaceuticals, Inc. (ADIL) announced on September 16, 2025, that it received favorable final meeting minutes from its End of Phase 2 (EOP2) Meeting with the FDA, providing formal input and alignment on the Phase 3 clinical development program for AD04.
- The FDA supported the proposed adaptive trial design for AD04, a drug for Alcohol Use Disorder (AUD), and confirmed zero heavy drinking days during months 5 and 6 as the primary efficacy endpoint.
- This positive feedback is considered a key milestone for advancing AD04 toward registration and is expected to accelerate strategic partnership discussions.
- A new patent filing for AD04 could potentially extend market exclusivity to 2045.
Sep 16, 2025, 12:05 PM
Adial Pharmaceuticals Receives Nasdaq Extension for Minimum Bid Price Compliance
ADIL
Delisting/Listing Issues
- Adial Pharmaceuticals, Inc. (ADIL) has been granted a 180-calendar day extension by Nasdaq to regain compliance with the minimum $1.00 bid price requirement.
- The new deadline for the company to meet the Nasdaq Listing Rule 5550(a)(2) is March 2, 2026.
- To regain compliance, the company's common stock must maintain a closing bid price of at least $1.00 per share for a minimum of ten (10) consecutive business days.
- This extension has no immediate effect on the listing or trading of the company's shares on the Nasdaq Capital Market.
- The company intends to monitor its stock price and may consider a reverse stock split to cure the deficiency.
Sep 3, 2025, 12:48 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more